{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"60","value":"22"},{"groupId":"OG001","lowerLimit":"6","upperLimit":"61","value":"27"},{"groupId":"OG002","lowerLimit":"10","upperLimit":"82","value":"43"},{"groupId":"OG003","lowerLimit":"5","upperLimit":"85","value":"40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Complete and Partial Tumor Response by RECIST 1.1. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v.1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR),.\\>=30% decrease in the sum of the longest diameter of target lesions; Overall response (OR) = CR + PR","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm I (Carboplatin and Paclitaxel)"},{"description":"Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCapecitabine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nOxaliplatin: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG001","title":"Arm II (Oxaliplatin and Capecitabine)"},{"description":"Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG002","title":"Arm III (Carboplatin, Paclitaxel, Bevacizumab)"},{"description":"Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.\n\nBevacizumab: Given IV\n\nCapecitabine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nOxaliplatin: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG003","title":"Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)"}],"paramType":"NUMBER","populationDescription":"All randomized patients with measurable disease","reportingStatus":"POSTED","timeFrame":"CT scan or MRI if used to follow lesion for measurable disease every other cycle for the first 6 months; then every 3 months x 2; then every 6 months thereafter until disease progression, and any other time clinically indicated, up to 5 years","title":"Objective Tumor Response","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}